AlloVir CMO Agustin Melian to depart at year-end; Richard Riese to lead clinical programs

Kalaris Therapeutics, Inc.

CMO Agustin Melian, MD, leaves AlloVir at end of 2021 after two and a half years.
Melian will serve in an advisory role for transition; CEO thanked him for advancing posoleucel into Phase 3.
Richard Riese, MD, PhD, SVP Clinical Research, will oversee clinical development including Phase 3 posoleucel studies.
Company's pipeline of virus-specific T cells continues; no change to clinical strategy disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.